Since T2DM is characterized by hyperglycemia, the potential role of IGFBP2 in T2DM induced breast cancer, and particularly as a therapeutic target to increase chemo-sensitivity of breast cancer cells seems plausible. This evidence concerns the gene IGFBP2 and Hyperglycemia.